Condition: Renal Cancer · Renal Clear Cell Carcinoma · Lymphoma · Sponsor: RenJi Hospital
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.
This description comes directly from the study's public registry record.
Weijun Wei, Ph.D. & M.D. · 15000083153 · wwei@shsmu.edu.cn
Always discuss trial participation with your own doctor first.
| Renji Hospital, School of Medicine, Shanghai Jiao Tong University | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06852638